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Various DNA alterations can be caused by exposure to environmental and endogenous carcinogens. Most of 
these alterations, if not repaired, can result in genetic instability, mutagenesis and cell death. DNA repair 
mechanisms are important for maintaining DNA integrity and preventing carcinogenesis. Recent lung cancer 
studies have focused on identifying the effects of single nucleotide polymorphisms (SNPs) in candidate genes, 
among which DNA repair genes are increasingly being studied. Genetic variations in DNA repair genes are 
thought to modulate DNA repair capacity and are suggested to be related to lung cancer risk. We identified a 
sufficient number of epidemiologic studies on lung cancer to conduct a meta-analysis for genetic polymor-
phisms in nucleotide excision repair pathway genes, focusing on xeroderma pigmentosum group A (XPA), exci-
sion repair cross complementing group 1 (ERCC1), ERCC2/XPD, ERCC4/XPF and ERCC5/XPG. We found an 
increased risk of lung cancer among subjects carrying the ERCC2 751Gln/Gln genotype (odds ratio (OR) = 1.30, 
95% confidence interval (CI) = 1.14 - 1.49). We found a protective effect of the XPA 23G/G genotype (OR = 0.75, 
95% CI = 0.59 - 0.95). Considering the data available, it can be conjectured that if there is any risk association 
between a single SNP and lung cancer, the risk fluctuation will probably be minimal. Advances in the identifica-
tion of new polymorphisms and in high-throughput genotyping techniques will facilitate the analysis of multi-
ple genes in multiple DNA repair pathways. Therefore, it is likely that the defining feature of future epidemi-
ologic studies will be the simultaneous analysis of large samples. 
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1.  Introduction 
Sporadic cancer is a multifactorial disease that 
results from complex interactions between many ge-
netic and environmental factors [1]. This means that 
there will not be a single gene or single environmental 
factor that has large effects on cancer susceptibility. 
Environmental factors (e.g. tobacco smoke, dietary 
factors, infectious agents and radiation) add to the 
carcinogenic load to which humans are exposed, but 
exact numbers for added risk are generally less well 
established.  
 Cancer is the result of a series of DNA alterna-
tions in a single cell or clone of that cell, which leads 
to a loss of normal function, aberrant or uncontrolled 
cell growth and often metastasis. Several of the genes 
that are frequently lost or mutated have been identi-
fied, including genes that function to induce cell pro-
liferation under specific circumstances (e.g. the ras 
and myc proto-oncogenes) and those which are pro-
grammed to halt proliferation in damaged cells (e.g. 
the  TP53 and RB1 tumor suppressor genes). Other 
mutations in genes involved in DNA repair are also 
necessary. About 150 human DNA repair genes have 
been identified to date [2], but the real number is 
probably higher, since less than 50% of known and 
putative genes have an identified function. The asso-
ciation between defects in DNA repair and cancer was 
established by Cleaver in 1968 [3], who showed that 
xeroderma pigmentosum (XP) is caused by deficient 
nucleotide excision repair (NER). For more than a 
quarter of a century after that it was thought that only 
rare syndromes, such as XP, Cockayne syndrome (CS) 
and ataxia telangiectasia, were associated with DNA 
repair defects [4]. Novel, common polymorphisms in 
DNA repair genes are continuously being identified, 
and these polymorphisms may play a pivotal role in 
sporadic carcinogenesis. A growing body of literature, 
including observations of inter-individual differences 
in measures of DNA damage, suggests that these 
polymorphisms may alter the functional properties of 
DNA repair enzymes. 
 At least four pathways of DNA repair operate on 
specific types of damaged DNA. Base excision repair 
(BER) operates on small lesions, while the NER path-
way repairs bulk lesions. Mismatch repair corrects 
replication errors. Double-strand DNA break repair 
(DSBR) actually consists of two pathways, homolo-Int. J. Med. Sci. 2007, 4 
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gous recombination (HR) and non-homologous 
end-joining (NHEJ). The NHEJ repair pathway in-
volves direct ligation of the two double strand break 
ends, while HR is a process by which double-strand 
DNA breaks are repaired through the alignment of 
homologous sequences of DNA. The following sec-
tions review the literature on DNA repair genes in 
more detail, specifically those involved in the NER 
pathway. 
  NER is a versatile DNA repair system that re-
moves a wide range of DNA lesions including 
UV-induced lesions. There are two subpathways in 
NER. One is transcription-coupled DNA repair (TCR), 
which preferentially removes DNA damage that 
blocks ongoing transcription in the transcribed DNA 
strand of active genes. The other is global genome re-
pair (GGR), which removes lesions throughout the 
genome, including those from the nontranscribed 
strand in the active gene [5]. Three rare, autosomal 
recessive inherited human disorders are associated 
with impaired NER activity: XP, CS and trichothio-
dystrophy (TTD) [6]. XP has been studied most exten-
sively. XP patients develop skin tumors at an ex-
tremely high frequency (1000 fold increased incidence 
as compared to normal individuals) because of their 
inability to repair UV-induced DNA lesions. These 
clinical findings are associated with cellular defects, 
including hypersensitivity to killing and the 
mutagenic effects of UV and the inability of XP cells to 
repair UV-induced DNA damage [7]. Approximately 
80% of XP patients who have been classified have a 
defect in the NER pathway. These patients are said to 
have "classical" XP, in contrast to the remaining 20% of 
patients who are designated as XP variants (XPV) and 
most likely have a defect in post-replication repair. In 
XPV patients, DNA replication stops or is interrupted 
at sites of UV-damage. Furthermore, de novo DNA 
synthesis opposite cyclobutane pyrimidine dimer le-
sions is prone to errors, leading to the fixation of mul-
tiple DNA mutations and ultimately to cancer. Seven 
different DNA NER genes, which correct seven dis-
tinct genetic XP complementation groups (XPA, XPB 
(ERCC3), XPC, XPD (ERCC2), XPE, XPF (ERCC4) and 
XPG (ERCC5, this gene causes CS)) and XPV have 
been identified [6]. XPA, ERCC3/XPB, ERCC2/XPD, 
ERCC4/XPF and ERCC5/XPG have a defect in TCR 
and GGR, while XPC and XPE have a defect in GGR 
only. ERCC6 and ERCC8 are also known as CS type B 
(CSB) and CSA, respectively. Approximately 20% of 
patients have been assigned to the CSA complementa-
tion group Essentially CS shows some overlap with 
certain forms of XP. In contrast to XP and TTD, 
however, the NER defect in CS is limited to the 
TCR pathway. As with XP, TTD involves mutations 
in XP genes, usually XPD, which encodes a compo-
nent of the transcription factor TFIIH [8]. However, it 
has been suggested that the functions of XPD associ-
ated with TTD are distinct from those of XPD associ-
ated with XP. Approximately half of the patients with 
TTD display photosensitivity, correlated with the NER 
defect.  
  The aim of this article is to review and evaluate 
associations between genes in the NER pathway and 
lung cancer risk, focusing on genes encoding five key 
enzymes in this pathway: XPA, ERCC1, ERCC2/XPD, 
ERCC4/XPF and ERCC5/XPG.   
2.  Materials and methods 
2-1. Identification and eligibility of relevant studies 
We conducted MEDLINE, Current Contents and 
Web of Science searches using "XPA", "ERCC1", 
"ERCC2/XPD", "ERCC4/XPF", "ERCC5/XPG", "lung 
cancer" and "polymorphism" as keywords to search 
for papers published (from January 1, 1966 through 
May 31, 2006). Additional articles were identified 
through the references cited in the first series of arti-
cles selected. Articles included in the meta-analysis 
were in any language, with human subjects, published 
in the primary literature and had no obvious overlap 
of subjects with other studies. We excluded studies 
with the same data or overlapping data by the same 
authors. Case-control studies were eligible if they had 
determined the distribution of the relevant genotypes 
in lung cancer cases and in concurrent controls using a 
molecular method for genotyping. Using the 
MEDLINE database, we identified 5 genetic epidemi-
ological studies [9-13] that provided information on 
lung cancer occurrence associated with the XPA G23A 
polymorphism (one of the identified 6 candidate stud-
ies was excluded due to overlapping data [11]). We 
identified 5 studies of the ERCC1 T19007C polymor-
phism (all of 5 candidate studies were independent 
[13-17]). We gathered 18 articles on the ERCC2 
312/751 polymorphisms found through literature 
searches and checked their references for additional 
relevant studies. Of the relevant 18 studies, 2 studies 
appeared to be on populations already reported [14, 
18, 19], leaving 15 independent studies (11 studies for 
the Asp312Asn polymorphism [11, 13, 14, 17-24] and 
14 studies for the Lys751Gln polymorphism [11, 13, 14, 
17-19, 21-28]. Less than 5 studies each have been re-
ported on the ERCC1 C8092A, ERCC4/XPF Arg415Gln, 
ERCC4/XPF Ser835Ser, ERCC5/XPG His46His, 
ERCC5/XPG Asp1104His SNPs.   
2-2. Data extraction and assessment of study quality 
  For each study, characteristics such as authors, 
year of publication, ethnic group of the study popula-
tion, source of control population, number of geno-
typed cases and controls, crude odds ratio (OR) and 
the method for quality control of genotyping were 
noted. For studies including subjects of different eth-
nic groups, data were extracted separately for each 
ethnic group whenever possible.   
  Methods for defining study quality in genetic 
studies are more clearly delineated than those for ob-
servational studies. We assessed the homogeneity of 
the study population (Caucasian or Asian). 
2-3. Meta-analysis 
  Data were combined using both a fixed effects 
(the inverse variance-weighted method) and a random 
effects (DerSimonian and Laird method) models [29]. Int. J. Med. Sci. 2007, 4 
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The Cochrane Q statistics test is used for the assess-
ment of heterogeneity. The fixed effects model is used 
when the effects are assumed to be homogenous, 
while the random effects model is used when they are 
heterogenous. In the absence of between-study het-
erogeneity, the two methods provide identical results. 
The presence of heterogeneity can result from differ-
ences in the selection of controls, age distribution, 
prevalence of lifestyle factors, histologic type of lung 
cancer, stage of lung cancer and so on. The random 
effects model incorporates an estimate of the be-
tween-study variance and tends to provide wider CIs 
when the results of the constituent studies differ 
among themselves. As the random effects model is 
more appropriate when heterogeneity is present [29], 
the summary OR and prevalence were essentially 
based on the random effects model. The meta-analyses 
were performed on crude ORs, since the adjusted ORs 
were not comparable because of the inclusion of dif-
ferent covariates in the multivariate regression models. 
Using individuals with the homozygous common 
genotype as the reference group, we calculated ORs 
for individuals with the heterozygous genotype and 
homozygous rare genotype separately whenever pos-
sible (information available in at least two studies). In 
some cases, we combined the heterozygous genotype 
with the homozygous rare genotype due to a low 
prevalence of the rare allele in several polymorphisms. 
The Q statistic was considered significant for P<0.10 
[30, 31]. Publication bias is always a concern in 
meta-analysis. The presence of publication bias indi-
cates that nonsignificant or negative findings remain 
unpublished. To test for publication bias, both Begg's 
[32] and Egger's [33] tests are commonly used to as-
sess whether smaller studies reported greater associa-
tions than larger studies. Publication bias is consid-
ered significant for P<0.10. Publication bias may be 
always a possible limitation of combining data from 
various sources as in a meta-analysis. The idea of ad-
justing the results of meta-analyses for publication 
bias and imputing "fictional" studies into a 
meta-analysis is controversial at the moment [34]. 
Sutton et al. concluded that publication or related bi-
ases did not affect the conclusions in most 
meta-analyses because missing studies changed the 
conclusions in less than 10% of meta-analyses [34]. All 
of the calculations were performed using STATA Ver-
sion 8.2 (Stata Corporation, College Station, TX) soft-
ware. 
3.  Results 
3-1. DNA repair capacity and lung cancer risk 
Cigarette smoke contains several thousand 
chemicals that are known to chemically modify DNA 
[35] and lead to the formation of mutations [36]. Most 
of these compounds are procarcinogens that must be 
activated by Phase I enzymes, such as cytochrome 
P450s. All activated carcinogens can bind to DNA and 
form DNA adducts that are capable of inducing muta-
tions and initiating carcinogenesis. The capacity to 
repair DNA damage induced by activated carcinogens 
appears to be one of the host factors that may influ-
ence lung cancer risk. A critical cellular response that 
counteracts the carcinogenic effects of DNA damage is 
DNA repair. As stated earlier, there are several known 
pathways of DNA repair, all of which act to remove 
DNA lesions and prevent mutations, thereby restoring 
genetic integrity. 
Several studies have investigated whether re-
duced DNA repair capacity (DRC) is associated with 
an increased risk of cancer [37]. The reduced DRC of 
benzo(a)pyrene-7,8-diol-9,10-epoxide (an active form 
of benzo(a)pyrene)-DNA adducts is associated with 
an increased risk of lung cancer (2.1-fold, 95% confi-
dence interval (CI) = 1.5 - 3.0) [38]. The reduced DRC 
has been shown to be associated with a 5.7-fold (95% 
CI = 2.1 - 15.7) increased risk of developing lung can-
cer [39]. Likewise, the reduced DRC of bleomy-
cin-induced damage was found to be associated with 
an increased risk of lung cancer [40]. These studies 
suggested that a low DRC of various DNA repair 
mechanisms predisposes individuals to lung cancer, 
and this realization prompted us to search for defined 
DNA repair activities that may be risk factors for lung 
cancer. Polymorphisms in DNA repair genes may be 
associated with differences in the DRC of DNA dam-
age and may influence an individual's risk of lung 
cancer, because the variant genotype in those poly-
morphisms might destroy or alter repair function. 
3-2. XPA G23A polymorphism and lung cancer risk 
The heterotrimeric replication protein A (RPA) is 
required for NER and may play an important role in 
the damage recognition process. The XPA protein is 
required for NER and is involved in the DNA damage 
recognition process. Both RPA and XPA preferentially 
bind damaged DNA, and because RPA and XPA di-
rectly interact in the absence of DNA, the RPA-XPA 
complex has been implicated as a key component in 
the earliest stage of damage recognition [41]. There is 
also evidence that the XPC-hHR23B protein complex 
may initiate recognition of DNA damage for the 
global genomic repair pathway of NER [42]. Recent 
evidence also implicates the damaged DNA binding 
protein heterodimer in damage recognition, because 
the complex binds damaged DNA with high affinity 
[43] and can dramatically increase the repair rate of 
certain DNA adducts, including cyclobutane 
pyrimidine dimers, in conjunction with XPA and RPA 
[44].  
The XPA maps on chromosome 9, at 9q22.3. In 
the XPA gene, a polymorphic site was identified that 
was in the 5' untranslated region (UTR) of the gene 
and which consisted of a G-to-A (or A-to G) substitu-
tion in the fourth nucleotide before the ATG start 
codon (dbSNP rs 1800975) [45]. SNP alleles with 
higher frequencies are more likely to be ancestral than 
less frequently occurring alleles although there may be 
some exceptions. As the 23G allele was more preva-
lent than the 23A allele (Table 1), we regarded the 23G 
allele as ancestral (wild-type or major) allele for de-
scriptive purposes (the XPA 23 polymorphism caused 
by the G-to-A substitution is the XPA G23A poly-Int. J. Med. Sci. 2007, 4 
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morphism). The polymorphism, termed the XPA 
G23A polymorphism (at position 23 in the transcript, 
four nucleotides upstream of the start codon), is in the 
Kozak sequence near the start codon and thus may 
affect the XPA protein levels in cells [46]. A functional 
association between the XPA G23A polymorphism 
and DRC has been reported [10]. It has been shown 
that healthy subjects with at least one 23G allele have 
significantly higher DRC. When the combined A/A 
and A/G genotype was used as the reference, the 
G/G genotype was associated with a significantly de-
creased risk of lung cancer (adjusted OR = 0.56, 95% 
CI = 0.35 - 0.90) in Koreans [9]. A significant protective 
effect of the combined G/A and G/G genotypes on 
lung cancer risk was reported in Americans (adjusted 
OR = 0.69, 95% CI = 0.53 - 0.90) and Mexi-
can-Americans (adjusted OR = 0.32, 95% CI = 0.12 - 
0.83) [10]. Likewise, a protective and nonsignificant 
effect was seen among Germans [11] and Danes [12]. 
As compared with the combined G/A and A/A 
genotypes, the G/G genotype was, however, associ-
ated with a significantly increased risk of lung cancer 
(adjusted OR = 1.59, 95% CI =1.12 - 2.27) in a Norwe-
gian population [13]. Summary frequencies of the 23A 
allele among all and Caucasian populations, based on 
the random effects model, were 0.368 (95% CI = 0.308 - 
0.429) and 0.352 (95% CI = 0.277 - 0.428), respectively 
(Table 1). Summary ORs for the G/A genotype and 
G/G genotype among 5 studies in 7 populations were 
0.73 (95% CI = 0.61 - 0.89) and 0.75 (95% CI = 0.59 - 
0.95), respectively (Table 1). Evidence for heterogene-
ity was absent in both analyses. Among Caucasian 
studies, the summary ORs for the G/A genotype and 
the A/A genotype were 0.72 (95% CI = 0.58 - 0.89) and 
0.82 (95% CI = 0.61 - 1.11), respectively. The Cochrane 
Q test for heterogeneity did not show a statistical sig-
nificance. The Egger's test was statistically significant 
for publication bias in a subgroup analysis of Cauca-
sians (P = 0.073, G/A genotype vs. G/G genotype). 
Two studies investigated associations between 
cigarette smoking and the G23A polymorphism in 
relation to lung cancer. When stratifying by smoking 
status, there was a significant protective effect for 
current smokers who possessed the G/G genotype 
(adjusted OR = 0.23, 95% CI = 0.07- 0.71) but not for 
former or never smokers [9]. Ever smokers (current 
and former) with at least one copy of the 23G allele 
showed a significantly reduced risk of lung cancer 
(adjusted OR = 0.68, 95% CI = 0.51 - 0.91) among Cau-
casians [10]. The presence of the 23A polymorphism, 
however, was associated with a statistically significant 
reduced risk in subjects who smoked >29 pack-years 
(OR = 0.53, 95% CI = 0.17 - 0.97) [13]. Interactions be-
tween cigarette smoking and the polymorphism were 
not determined in the studies [9, 10, 13]. No associa-
tions were seen between the G23A polymorphism and 
any histologic types of lung cancer [11], while the 
G/G genotype was associated with a significantly de-
creased risk for small cell lung cancer (OR = 0.23, 95% 
CI = 0.07 - 0.71) [9].   
The  XPA G23A polymorphism may, thus, be a 
promising SNP for lung cancer. It is thought that 
cigarette smoking modifies the association between 
DNA repair polymorphisms, as well as metabolic 
polymorphisms, and lung cancer risk. Since interac-
tions between the G23A polymorphism and smoking 
have not been fully elucidated, further studies are 
needed to better understand the associations between 
the XPA G23A polymorphism and lung cancer risk. 
3-3. ERCC1 polymorphisms and lung cancer risk 
The  ERCC1 coding region is 1.1 kb long and 
comprises 10 exons. This gene is located on 19q13.2 - 
q13.3. Shen et al. [47] have identified polymorphisms 
of three of the exons of the ERCC1 gene, all of which 
resulted in silent mutations. No amino acid substitu-
tions were observed among the ERCC1 polymor-
phisms [48]. The functional effects of the silent poly-
morphisms in ERCC1 have not been fully elucidated; 
however, some of the variant alleles of the polymor-
phisms in DNA repair genes may be associated with 
the reduced DRC. The studies have focused on poly-
morphisms of the 3′ UTR (C8092A, dbSNP no. 
rs3212986) and codon 118 (Asn118Asn, T19007C, 
dbSNP no. rs11615) in ERCC1. 
For the T19007 C (Asn118Asn) polymorphism, 
although the T/T genotype generates the less com-
monly associated triplet codon sequence encoding the 
amino acid and has been termed the "variant" by con-
vention, the T/T genotype indeed has been reported 
to occur at higher frequencies. Hence, the T/T geno-
type is used as reference in this paper. The C/C geno-
type of the C8092A polymorphism is used as reference 
on the same score.   
The C/C genotype of the T19007C polymor-
phism was associated with a significantly decreased 
risk of lung cancer (adjusted OR = 0.32, 95% CI = 0.19 - 
0.55) in a Norwegian population [13]. A lack of asso-
ciation between the T19007C polymorphism and lung 
cancer risk was observed in a Danish population [14], 
a large American population [15], a Chinese popula-
tion [16] and a nonsmoking European population [17]. 
As shown in Table 2, summary frequencies of the 
19007T allele among all and Caucasian populations, 
based on the random effects model, were 0.499 (95% 
CI = 0.387 - 0.611) and 0.575 (95% CI = 0.529 - 0.622), 
respectively. The summary ORs for the T/C genotype 
and the C/C genotype were 0.82 (95% CI = 0.62 - 1.08) 
and 0.72 (95% CI = 0.46 - 1.11), respectively. Even if 
the analysis was restricted to Caucasian studies, the 
ORs did not materially change. The Cochrane Q test 
for heterogeneity showed a statistical significance in 
any analysis. In comparison of the T/C genotype with 
the T/T genotype, the Begg's test was statistically sig-
nificant in an overall analysis (P = 0.086) and a sub-
group analysis of Caucasians (P = 0.089). 
Two studies examined an interaction between 
the T19007C polymorphism and cigarette smoking. 
When stratified by smoking status, the interaction 
between smoking and the polymorphism was not sta-
tistically significant [15, 16]. Only one study provides 
information on the T19007C polymorphism and lung 
cancer risk in histologic types. There was no difference Int. J. Med. Sci. 2007, 4 
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in risk estimates according to the histological type of 
lung cancer [16].   
As for the C8092A polymorphism, no association 
was found between the polymorphism and lung can-
cer risk in Norwegians [13] and Americans [15]. The 
C8092A and T19007C polymorphisms have been re-
ported to be in linkage disequilibrium [15].   
Although harboring at least one 19007C allele 
may be associated with a deceased risk of lung cancer, 
the protective effect of the 19007C allele needs to be 
confirmed in other independent studies. Furthermore, 
additional studies are needed to detect the function of 
the ERCC1 polymorphisms. 
3-4. ERCC2/XPD polymorphisms and lung cancer 
risk  
The ERCC2/XPD protein plays a role in the NER 
pathway, which recognizes and repairs a wide range 
of structurally unrelated lesions such as bulky adducts 
and thymidine dimers. ERCC2/XPD works as an 
ATP-dependent (5'→3') helicase joined to the basal 
TFIIH complex used to separate the double helix. The 
ERCC2/XPD protein is necessary for normal tran-
scription initiation and NER. ERCC2/XPD maps on 
chromosome 19, at 19q13.3 and covers 21.14 kb. Muta-
tions in the ERCC2 gene can diminish the activity of 
TFIIH complexes, giving rise to repair defects, tran-
scription defects and abnormal responses to apoptosis 
[49]. 
A number of polymorphisms in the ERCC2/XPD 
gene have been reported. Whereas polymorphisms in 
the codons 199, 201 and 575 are rare, those in codons 
156, 312, 711 and 751 are common. Two ERCC2/XPD 
polymorphisms, Asp312Asn (db SNP no. rs1799793) 
and Lys751Gln (db SNP no. rs13181), have mainly 
been investigated in relation to phenotypic endpoints 
relevant to lung carcinogenesis. With regard to the 
Asp312Asn polymorphism, most of the reported data 
indicate a higher level of DNA adducts in subjects 
with the Asn allele. The interpretation of this finding 
is a lower DRC for the Asn allele than the Asp allele. 
This is also true for the ERCC2/XPD Lys751Gln poly-
morphism. The Gln allele is associated with a higher 
DNA adduct level or lower DRC.   
The Asp/Asp genotype of the ERCC2/XPD 
Asp312Asn polymorphism was found to have an in-
creased risk of lung cancer when the combined 
Asp/Asn and Asn/Asn genotypes served as reference 
(OR = 1.86, 95% CI =1.02 - 3.40) in Polish men [20]. A 
large American lung-cancer study also reported an 
elevated risk (adjusted OR = 1.5, 95% CI = 1.1 - 2.0; 
Asn/Asn genotype vs. Asp/Asp genotype) [18]. 
Likewise, Chinese subjects homozygous for the 
Asn/Asn genotype had an increased risk of lung can-
cer (adjusted OR = 10.33, 95% CI = 1.29 - 82.50) com-
pared with subjects homozygous for the Asp/Asp 
genotype [19]. No association with this polymorphism 
was seen in an admixed population [21], a small 
Swedish population [22] and among Finnish smoking 
men [23]. Two meta-analyses have been published in 
2004 [50] and 2005 [51], respectively. Both of them are 
based on the same published data from 6 individual 
case-control studies [18-23]. The first meta-analysis 
showed that individuals with the Asn/Asn genotype 
had a 27% (95% CI = 1.04 - 1.56) increased risk of lung 
cancer compared with individuals with the Asp/Asp 
genotype. The results supported the hypothesis that 
individuals with the Asn/Asn genotype are at higher 
risk of developing lung cancer [50]. The second 
meta-analysis was somewhat different from the first 
one, because unadjusted ORs were summarized in the 
first one. The summary OR associated with the 
Asn/Asn genotype was 1.18 (95% CI = 0.84 - 1.67). No 
significant association between the ERCC2/XPD 
Asp312Asn polymorphism and lung cancer was found 
in the second meta-analysis [51]. Regardless, these 
meta-analyses indicate that the excess lung cancer risk 
from the Asn/Asn genotype may be less than 30%. 
Five studies have been reported since the publi-
cation of these two meta-analyses. They revealed that 
the Asp312Asn polymorphism was not associated 
with lung cancer risk in Germans [11], Norwegians 
[13], Danes [14], Europeans [17] and Chinese [24]. 
As shown in Table 3, the summary frequency of 
the 312Asp allele among Caucasians (0.645, 95% CI = 
0.572 - 0.719) was significantly lower than that among 
Asians (0.936, 95% CI = 0.925 - 0.946). Summary ORs 
associated with the ERCC2/XPD Asp312Asn poly-
morphism are also shown in Table 3. No significant 
association between lung cancer and the heterozygous 
Asp/Asn genotype was found for all of the studies 
combined or by ethnicity. The Cochrane Q test for 
heterogeneity did not show a statistical significance in 
all analyses. Although no evidence of publication bias 
was found in overall analyses, both Begg's (P= 0.035) 
and Egger's (P = 0.003) tests showed a statistical sig-
nificance in a subgroup analysis of Caucasians 
(Asn/Asn genotype vs. Asp/Asp genotype). 
When stratifing by smoking dose, the risk of lung 
cancer was significantly higher in light-smokers with 
the Asp/Asp genotype than in those with the 
Asn/Asn genotype [20]. Similar findings were not 
seen for never-smoker or heavy-smokers [20]. A sig-
nificant interaction between smoking (smoking status, 
pack-years and duration) and the polymorphism was 
observed in one study [18] but not in two other studies 
[16,19]. Stratification analysis revealed that the in-
creased risk was mainly confined to squamous cell 
carcinoma of the lung, with the ORs being 20.50 (95% 
CI = 2.25 - 179.05) for the 312Asn/Asn genotype [19]. 
Table 4 shows the association between the 
ERCC2 Lys751Gln polymorphism and lung cancer risk. 
The Gln/Gln genotype was associated with an in-
creased risk for lung cancer compared with the 
751Lys/Lys genotype (adjusted OR = 2.71, 95% CI = 
1.01 - 7.24) in Chinese [19]. Stratification analysis re-
vealed that the increased risk was mainly confined to 
lung squamous cell carcinoma, with the OR being 4.24 
(95% CI = 1.34 - 13.38) for the Gln/Gln genotype [19], 
however. Although David-Beades et al. reported that 
the Gln/Gln genotype was associated with a signifi-
cantly increased risk of lung cancer in Caucasians Int. J. Med. Sci. 2007, 4 
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(USA), a multivariate-adjusted OR was no longer sig-
nificant [25]. No association with the Lys751Gln 
polymorphism was seen in two Caucasian popula-
tions [18, 22], an admixed population [21], a Finnish 
population [23], African-Americans [25], a Chinese 
population [26] and a Korean population [27]. The 
meta-analysis by Hu et al. (2004) showed that the 
Gln/Gln genotype had a 21% (95% CI = 1.02 - 1.43) 
increased risk of lung cancer compared with indi-
viduals with the Lys/Lys genotype [51]. The 
meta-analysis by Benhamou and Sarasin (2005) re-
ported that the summary OR for the Gln/Gln geno-
type was 1.18 (95% CI = 0.95 - 1.47) [51]. Both of the 
meta-analyses were based on the same published data 
from 8 individual case-control studies [18, 19, 21-23, 
25-27]. No significant association between the 
Lys751Gln polymorphism and lung cancer was found 
in the two meta-analyses [51]. These meta-analyses 
indicate that the excess lung cancer risk from the 
Gln/Gln genotype may be about 20%. Six studies [11, 
13, 14, 17, 24, 28] have been reported after the two 
meta-analysis. Danish subjects with the Gln/Gln 
genotype were at a 2.01-fold (95% CI = 1.20 - 3.35) 
h i g h e r  r i s k  o f  l u n g  c a n c e r  r i s k  t h a n  t h o s e  w i t h  t h e  
Lys/Lys genotype [14]. Similarly, the Gln/Gln geno-
type was associated with significantly increased risk 
of lung cancer (adjusted OR = 1.60, 95% CI = 1.10 - 
2.30) in Norwegians [13]. German individuals with the 
Gln/Gln genotype were at a borderline increased risk 
(adjusted OR = 1.59, 95% CI = 0.95 - 2.67) [11]. How-
ever, individuals with the Gln allele had a 61% (95% 
CI = 14 - 83) reduction of lung cancer risk in a Chinese 
population [24]. No association with the Lys751Gln 
polymorphism was seen in a European cohort [17] and 
in non-Hispanic Caucasians (USA) [28]. 
The summary frequency of the 751Lys allele 
among Caucasians (0.634, 95% CI = 0.614 - 0.655) was 
significantly lower than that among Asians (0.843, 
95% CI = 0.763 - 0.924). A statistically significant eth-
nic difference was observed between Caucasians and 
Asians. Summary ORs for the Gln/Gln genotype and 
Lys/Gln genotype were 1.06 (95% CI = 0.97 - 1.16) and 
1.30 (95% CI = 1.14 - 1.49), respectively. Evidence of 
publication bias was absent in all of the analyses. The 
e f f e c t  o f  t h e  G l n / G l n  g e n o t y p e  o n  l u n g  c a n c e r  r i s k  
was stronger in Caucasians (OR = 2.25, 95% CI = 0.97 - 
5.23) than in Asians (OR = 1.02, 95% CI = 0.20 - 5.27). 
This may only be due to a difference in sample sizes. 
Reasons for this difference in risk among different 
ethnic populations are as yet unknown but, if real, 
may be related to other genetic or environmental fac-
tors. The Cochrane Q test for heterogeneity showed a 
statistical significance among Asian studies (P = 0.040, 
Gln/Gln genotype vs. Lys/Lys genotype).   
There was no interaction between smoking 
(smoking status, pack-years and duration) and the 
polymorphism [14, 19, 26, 27]. Although the Lys/Lys 
genotype was associated with a statistically significant 
increased risk (OR = 2.0, 95% CI = 1.15 - 3.41) among 
subjects who smoked>29 pack-years, an interaction 
between cigarette smoking and the polymorphism 
was not determined [13]. When stratified by histo-
logical type, no statistically significant association 
between the polymorphism and lung cancer risk was 
found [26, 27]. 
Several studies have investigated the possible 
association of ERCC2/XPD Asp312Asn and Lys751Gln 
polymorphisms with lung cancer with inconsistent 
results. The Lys751Gln polymorphism has been more 
studied than the Asp312Asn polymorphism, because 
the frequency of the 751Gln allele is more prevalent 
than the 312Asn allele. The Asp312Asn polymorphism 
is in linkage disequilibrium with the Lys751Gln 
polymorphism [19, 20, 21], however. The inconsistent 
associations in previous studies of the ERCC2/XPD 
polymorphisms could be due to differences in study 
populations, the small sample sizes of earlier studies 
and possible environmental interactions.   
3-5. ERCC4/XPF polymorphisms and lung cancer 
risk 
ERCC4/XPF is an essential protein in the NER 
pathway, which is responsible for removing UV-C 
photoproducts and bulky adducts from DNA. Among 
the NER enzymes, ERCC4/XPF and ERCC1 are also 
uniquely involved in removing DNA interstrand 
cross-linking damage. The ERCC4/XPF-ERCC1 com-
plex, which makes incisions at the 5′ end of DNA 
loops, may contribute to the repair of large trinucleo-
tide repeat containing loops that are generated due to 
replication slippage and that are too long to be re-
paired by the postreplicative DNA mismatch repair 
system [52]. Polymorphisms in enzymes involved in 
large loop repair could be responsible for the observed 
variation in the stability of similar-sized trinucleotide 
repeat disease alleles among different individuals. The 
ERCC4/XPF gene is evolutionarily conserved. Exten-
sive homology exists between human ERCC4/XPF, 
Drosophila Mei-9, Saccharomyces cerevisiae RAD1, and S. 
pombe Rad16 [53], all of which have similar functions 
in NER. 
The  ERCC4/XPF gene contains 11 exons, spans 
28.2 kb and is located on chromosome 16p13.2 - p13.13. 
Several polymorphisms exist in the coding region of 
ERCC4/XPF, a few of which have been associated with 
cancer risks. Genetic instability of simple repeated 
sequences might also be influenced by the ERCC4/XPF 
polymorphisms. The ERCC4/XPF G1244A polymor-
phism is a G-to-A change in exon 8 (Arg415Gln, 
dbSNP no. rs1800067) that results in a change from 
arginine to glutamine. The ERCC4/XPF polymorphism 
in exon 8 has been reported to be associated with an 
increased risk for developing breast cancer [54]. The 
T2505C polymorphism is a T-to-C change in exon 11 
(Ser835Ser, dbSNP no. rs1799801) that results in no 
amino acid change (serine is conserved) [55]. Func-
tionally significant SNPs in the ERCC4/XPF gene may 
a l s o  c o n t r i b u t e  t o  i n d i v i d u a l  d i f f e r e n c e s  i n  t h e  f i n e  
details of DNA repair. A lack of association was found 
between the G1244A (Arg415Gln) polymorphism and 
lung cancer risk (adjusted OR = 1.11, 95% CI = 0.59 - 
2.07; Arg/Gln genotype vs. Arg/Arg genotype) in Int. J. Med. Sci. 2007, 4 
 
65
Koreans [9]. The C/C genotype of the T2505C poly-
morphism was nonsignificantly associated with an 
increased risk of lung cancer (adjusted OR = 1.71, 95% 
CI = 0.52 - 5.58) in Chinese [24].   
3-6. ERCC5/XPG polymorphisms and lung cancer 
risk 
ERCC5/XPG is responsible for a 1186 amino acid 
structure-specific endonuclease activity that is essen-
tial for the two incision steps in NER. The 
ERCC5/XPG nuclease has been suggested to act on 
the single-stranded region created as a result of the 
combined action of the XPB helicase and the 
ERCC2/XPD helicase at the DNA damage site. In 
human cells, ERCC5/XPG catalyses an incision ap-
proximately 5 nucleotides 3' to the site of damage but 
is also involved non-enzymatically in the subsequent 
5' incision. It is further involved in the stabilization of 
a pre-incision complex on the damaged DNA. 
The ERCC5/XPG gene contains 17 exons, spans 
32 kb and is located on chromosome 13q32.3 -q33.1. 
Several polymorphisms in the coding sequence of the 
EECC5/XPG gene have been identified. The associa-
tion between lung cancer and two common polymor-
phisms, T335C (His46His, dbSNP no. rs1047768) and 
G3507C (Asp1104His, dbSNP no. rs17655), have been 
investigated. The functional effects of these two SNPs 
are still unknown. However, it is likely that the SNPs 
in the coding DNA sequences may result in a subtle 
structural alteration of the ERCC5/XPG activity and 
modulation of lung cancer susceptibility.   
The Asp/Asp genotype of the Asp1104His poly-
morphism was associated with a significantly de-
creased risk of lung cancer (adjusted OR = 0.60, 95% 
CI = 0.38 - 0.95) in a Korean population [56]. Similarly, 
the Asp/Asp genotype was inversely associated with 
lung cancer (adjusted OR = 0.65, 95% CI = 0.39 - 1.1) in 
an admixed population (composed mostly composed 
of whites) [57]. However, the Asp/Asp genotype was 
not associated with lung cancer risk in a Chinese 
population [24]. As for T335C polymorphism, the C/C 
genotype was associated with a significantly increased 
risk of lung cancer (adjusted OR = 1.79, 95% CI = 1.19 - 
2.63) in Norwegians [13] but not in Chinese [24]. 
4.  Discussion 
Epidemiological studies of common polymor-
phisms in DNA repair genes, if large and unbiased, 
can provide insight into the in vivo relationships be-
tween DNA repair genes and lung cancer risk. Such 
studies may identify empirical associations which in-
dicate that a polymorphism in a gene of interest has an 
impact on lung cancer, independent of metabolic 
regulatory mechanisms and other genetic and envi-
ronmental variability. Findings from epidemiological 
studies can complement in vitro analyses of the vari-
ous polymorphisms, genes, and pathways. In addition, 
epidemiological studies of common polymorphisms 
can lead to an increased understanding of the public 
health dimension of DNA-repair variation. 
We conducted a systematic literature review to 
evaluate the associations between sequence variants in 
DNA repair genes and lung cancer risk. We found an 
increased risk of lung cancer among subjects carrying 
the  ERCC2/XPD 751Gln/Gln genotype (OR = 1.30, 
95% CI = 1.14 - 1.49). The Gln allele of the ERCC2/XPD 
Lys751Gln polymorphism is associated with a higher 
DNA adduct level or lower DNA repair efficiency, 
except in research published by Duell et al. (2000) who 
found no correlation between the ERCC2/XPD 
Lys751Gln polymorphism and the level of polyphe-
nol-DNA adducts in human blood samples [58]. 
Matullo et al. (2003) demonstrated a higher level of 
DNA adducts, measured by 32P-postlabeling, in lym-
phocytes from nonsmokers with the ERCC2/XPD 
751Gln/Gln genotype [59]. Similarly, Palli et al. (2001) 
reported a higher level of DNA adducts in workers 
with at least one Gln allele who were exposed to traf-
fic pollution in comparison with workers with the two 
common alleles [60]. An increased number of aromatic 
DNA adducts was found by Hou et al. (2002) in pe-
ripheral blood lymphocytes from subjects with the 
ERCC2/XPD 312Asn and ERCC2/XPD 751Gln alleles 
[22]. The combined Asn/Asn and Gln/Gln genotypes 
showed a higher level of DNA lesions than did other 
genotypes.  
In contrast, we found a protective effect of the 
XPG G23A G/G genotype (OR = 0.75, 95% CI = 0.59 - 
0.95) on lung cancer risk. The G23A polymorphism 
itself may alter the transcription and/or translation of 
the gene. Because this polymorphism is located in the 
vicinity of the translation initiation codon, it may alter 
translation efficiency. The nearby proximal nucleo-
tides to the AUG initiation codon are important for the 
initiation of translation because the 40S ribosomal 
subunit binds initially at the 5'-end of the mRNA [61]. 
The consensus sequence around the start codon is 
GCCRCCAUGG, which is known as the Kozak con-
sensus sequence [62]. The R at position -3 and the G 
just downstream of the start codon are especially im-
portant, and the lack of these bases leads to 
read-through of the start codon [63]. However, there 
has been no precise explanation of the mechanism by 
which the recognition of the start codon is aided by a 
purine at position -3 [62], which is the core nucleotide 
of the Kozak consensus. The polymorphism XPA 
G23A is a G/A transversion occurring 4 nucleotides 
upstream of the start codon of XPA and possibly im-
proving the Kozak sequence [9]. The sequences 
(CCAGAGAUGG) around the predicted initiator me-
thionine codon of the XPA gene agree with the Ko-
zak’s consensus sequence at positions -3 and +4 [64]. 
Although both the A and polymorphic variant G nu-
cleotides at the -4 position of the XPA g e n e  d o  n o t  
correspond to the original consensus Kozak sequence 
containing the nucleotide C at position -4, it is possible 
that a nucleotide substitution of A to G at position -4 
preceding the AUG codon may affect ribosomal bind-
ing and thus alter the efficiency of XPA protein syn-
thesis. To investigate whether the transition from G to 
A changes the translation efficiency, an in vitro tran-
scription/translation analysis and a primer extension 
assay of the initiation complex will be necessary in the Int. J. Med. Sci. 2007, 4 
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future. Furthermore, a functional association between 
the G23A polymorphism and DRC was reported [10], 
which showed significantly higher repair efficiency in 
healthy subjects with at least one G allele. An alterna-
tive explanation could be that the protective XPA 23G 
allele is in linkage disequilibrium with an allele from 
an adjacent gene which is the true susceptibility gene.   
Several DNA repair pathways are involved in the 
maintenance of genetic stability. The most versatile 
and important one is the NER pathway, which detects 
and removes bulky DNA adducts, including those 
induced by cigarette smoking [65]. However, there are 
several conflicting reports on the association between 
this polymorphism and lung cancer risk among vari-
ous populations. Although the reasons for the incon-
sistencies in the studies are not clear, possible expla-
nations are: 1) low frequency of the "at-risk" genotype, 
which would reduce the statistical power of the stud-
ies and 2) small size of the studies. Ethnic differences 
in the roles of the polymorphism may be caused by 
gene-gene interactions, different linkages to the poly-
morphisms determining lung cancer risk and different 
lifestyles.  
The most important problems facing lung cancer 
research are identifying "at-risk" individuals and im-
plementing clinical surveillance, prevention practices, 
and follow-up care. Repair pathways play an impor-
tant role in lung cancer risk, and genetic variations 
may contribute to decreased DRC and lung cancer 
susceptibility. Although the increased/decreased risk 
associated with individual DNA repair SNPs may be 
small compared to that conferred by high-penetrance 
cancer genes, their public health implication may be 
large because of their high frequency in the general 
population. It is thus essential that epidemiological 
investigations of DNA repair polymorphisms are 
adequately designed. Unfortunately a fairly good 
number of studies are limited by their sample size and 
subsequently suffer from too low power to detect ef-
fects that may truly exist. Also, given the borderline 
significance of some associations and multiple com-
parisons that have been carried out, there is a possibil-
ity that one or more findings are false-positives [66]. 
Large and combined analyses may be preferred to 
minimize the likelihood of both false-positive and 
false-negative results. In addition, controls should be 
chosen in such a way that, if they were cases, they 
would be included in the case group; when controls 
are matched to cases, it is essential to account for 
matching in the analysis. When appropriate, con-
f o u n d i n g  f a c t o r s  s h o u l d  b e  c o n t r o l l e d  f o r ,  w i t h  p a r -
ticular consideration of race and ethnicity. An addi-
tional major concern is the grouping of genotypes for 
calculation of ORs. Without functional data to dictate 
genotype groupings, it seems prudent to present two 
ORs per polymorphism (one for heterozygotes vs. 
common-allele homozygotes and one for rare-allele 
homozygotes vs. common-allele homozygotes) so that 
dominant, codominant, or recessive patterns may be 
elucidated.  
Continued advances in SNP maps and in 
high-throughput genotyping methods will facilitate 
the analysis of multiple polymorphisms within genes 
and the analysis of multiple genes within pathways. 
The effects of polymorphisms are best represented by 
their haplotypes. Data from multiple polymorphisms 
within a gene can be combined to create haplotypes, 
the set of multiple alleles on a single chromosome. 
None of the studies reviewed here reported haplotype 
associations, although several studies analyzed multi-
ple polymorphisms within a gene, sometimes with 
inconsistent results. The analysis of haplotypes can 
increase the power to detect disease associations be-
cause of higher heterozygosity and tighter linkage 
disequilibrium with disease-causing mutations. In ad-
dition, haplotype analysis offers the advantage of not 
assuming that any of the genotyped polymorphisms is 
functional; rather, it allows for the possibility of an 
ungenotyped functional variant to be in linkage dis-
equilibrium with the genotyped polymorphisms [67]. 
An analysis of data from multiple genes within the 
same DNA-repair pathway (particularly those known 
to form complexes) can provide more comprehensive 
insight into the studied associations. Such an analysis 
may shed light on the complexities of the many path-
ways involved in DNA repair and lung cancer devel-
opment, providing hypotheses for future functional 
studies. Because of concerns over inflated type I error 
rates in pathway-wide or genome-wide association 
studies, methods of statistical analysis seeking to ob-
viate this problem are under development [68]. The 
ability to include haplotype information and data 
from multiple genes, and to model their interactions, 
will provide more powerful and more comprehensive 
assessments of the DNA repair pathways.   
This review, which is limited by the bias against 
publication of null findings, highlights the complexi-
ties inherent in epidemiological research and, particu-
larly, in molecular epidemiological research. There is 
evidence that some polymorphisms in DNA repair 
genes play a role in carcinogenesis, most notably the 
ERCC2/XPD Lys751Gln and XPA G23A polymor-
phisms. The variant allele of each of the three poly-
morphisms was associated with about a 30% decrease 
or increase in lung cancer risk. Although the summary 
risk for developing lung cancer in individuals of each 
genotype may not be large, lung cancer is such a 
common malignancy that even a small increase in risk 
can translate to a large number of excess lung cancer 
cases. Therefore, polymorphisms, even those not 
strongly associated with lung cancer, should be con-
sidered as potentially important public health issues. 
In addition, it is important to keep in mind that a sus-
ceptibility factor in one population may not be a factor 
in another. There are differences in the prevalence of 
DNA repair polymorphisms across populations. In a 
population where the prevalence of an "at-risk" geno-
type in a given polymorphism is very low, the 
"at-risk" allele or "at-risk" genotype may be too infre-
quent to assess its associated risk. At a population 
level, the attributable risk must be small simply be-
cause it is an infrequent allele. Finally, the major bur-Int. J. Med. Sci. 2007, 4 
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den of lung cancer in the population probably results 
from the complex interaction between many genetic 
and environmental factors over time. Most environ-
mental carcinogens first require metabolic activation 
by Phase I enzymes to their ultimate forms which then 
bind to DNA, forming aromatic-DNA adducts that are 
thought to be an early step in tumorigenesis. On the 
other hand, these activated forms are detoxified by 
Phase II enzymes. Thus, genetically determined sus-
ceptibility to lung cancer may depend on the meta-
bolic balance among Phase I enzymes, Phase II en-
zymes and DNA repair enzymes [69]. Further investi-
gations of the combined effects of polymorphisms 
between DNA repair genes and drug-metabolizing 
genes may also help to clarify the influence of genetic 
variation in the carcinogenic process. Consortia and 
international collaborative studies, which may be a 
way to maximize study efficacy and overcome the 
limitations of individual studies, are needed to help 
further illuminate the complex landscape of lung can-
cer risk and genetic variations.   
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Tables 
Table 1. Genetic polymorphisms in the NER pathway and lung cancer risk: XPA G23A polymorphism 
OR (95% CI)**  Author, published 
year (reference no.) 
Ethnicity No.  of 
Cases  
/Controls 
Source of 
controls 
Frequency of A 
allele (p*) 
G/A G/G 
Quality control of 
genotyping 
Park et al., 2002 [9]  Asian  265/185  Population  0.478 (0.140)  1.00 (0.62 
- 1.62) 
0.62 (0.35 
- 1.10) 
Sequencing 
Wu et al., 2003 [10]  Caucasian  564/581  Population  0.446 (0.066)  0.65 (0.48 
- 0.87) 
0.74 (0.55 
- 1.01) 
None 
Wu et al., 2003 [10]  Mexican-American  50/47  Population  0.394 (0.057)  0.31 (0.09 
- 1.00) 
0.40 (0.13 
- 1.25) 
None 
Wu et al., 2003 [10]  African-American  71/67  Population  0.299 (0.193)  0.54 (0.16 
- 1.68) 
0.49 (0.15 
- 1.49) 
None 
Popanda et al., 2004 
[11] 
Caucasian  461/457  Hospital  0.334 (0.682)  0.77 (0.48 
- 1.21) 
0.82 (0.52 
- 1.30) 
Replication (ran-
dom samples) 
Vogel et al., 2005 [12]  Caucasian  256/269  Population  0.268 (0.019)  0.78 (0.41 
- 1.49) 
0.57 (0.30 
- 1.06) 
None 
Zienolddiny et al., 
2006 [13] 
Caucasian  248/276  Population  0.361 (0.033)  0.87 (0.48 
- 1.57) 
1.41 (0.79 
- 2.52) 
Replication (all 
samples) 
Summary†  No. of populations             
All 
 
7 
 
1913/1882 
 
 0.368 
(0.308 - 0.429) 
0.73 (0.61 
- 0.89) 
p‡ = 
0.562 
0.75 (0.59 
- 0.95) 
p‡ = 
0.272 
 
Caucasian 4  1527/1583    
0.352 
(0.277 - 0.428) 
0.72 (0.58 
- 0.89) 
p‡ = 
0.805 
0.82 (0.61 
- 1.11) 
p‡ = 
0.169 
 
* P for difference of allelic frequency between cases and controls. 
** Crude odds ratio and 95% confidence interval. 
† Based on random effects model. 
‡ P for heterogeneity (Cochran Q test). 
Table 2. Genetic polymorphisms in the NER pathway and lung cancer risk: ERCC1 T19007C polymorphism 
OR (95% CI)**  Author, published year 
(reference no.) 
Ethnicity No.  of 
Cases 
/Controls 
Source of 
controls 
Frequency of T 
allele (p*) 
T/C C/C 
Quality control of 
genotyping 
Vogel et al., 2004 [14]  Caucasian  252/266  Population  0.617 (0.632)  0.99 (0.67 
- 1.47) 
0.86 (0.49 
- 1.50) 
Replication (ran-
dom samples) 
Zhou et al., 2005 [15]  Caucasian  1752/1358   
Population 
 
0.609 (0.875) 
 
1.00 (0.86 
- 1.17) 
 
1.02 (0.82 
- 1.27) 
Replication (ran-
dom samples) 
Yin et al., 2006 [16]  Asian  151/143  Hospital  0.203 (0.940)  0.39 (0.08 
- 1.53) 
0.49 (0.11 
- 1.84) 
Replication (ran-
dom samples) 
Zienolddiny et al., 2006 
[13] 
Caucasian  260/213  Population  0.462 (00004)  0.50 (0.31 
- 0.79) 
0.35 (0.20 
- 0.61) 
Replication (all 
samples) 
 
Matullo et al., 2006 [17] 
Caucasian 116/1093  Population  0.598 (0.423)  0.82 (0.52 
- 1.27) 
0.85 (0.46 
- 1.51) 
Replication (ran-
dom samples) 
Summary†  No. of popu-
lations 
          
All 
 
5 
 
2531/3073 
 
 0.499 
(0.387 - 0.611) 
0.82 (0.62 
- 1.08) 
p‡ = 
0.053 
0.72 (0.46 
- 1.11) 
p‡ = 
0.012 
 
Caucasian 4  2380/2930    
0.575 
(0.529 - 0.622) 
0.84 (0.63 
- 1.11) 
p‡ = 
0.046 
0.74 (0.46 
- 1.17) 
p‡ = 
0.007 
 
* P for difference of allelic frequency between cases and controls. 
** Crude odds ratio and 95% confidence interval. 
† Based on random effects model. 
‡ P for heterogeneity (Cochran Q test). Int. J. Med. Sci. 2007, 4 
 
70
Table 3. Genetic polymorphisms in the NER pathway and lung cancer risk: ERCC2 Asp312Asn polymorphism  
OR (95% CI)**  Author, published 
year (reference no.) 
Ethnicity  No. of Cases 
/Controls 
Source of 
controls 
Frequency of 
Asp allele (p*) 
Asp/Asn Asn/Asn 
Quality control 
of genotyping 
Butkiewicz et al., 
2001 [20] 
Caucasian  96/94  Population  0.564 (0.187)  0.49 (0.24 - 
0.98) 
0.71 (0.29 - 
1.74) 
Sequencing 
Spitz et al., 2001 [21]  Admixed 
population 
195/257  Population  0.728 (0.509)  0.92 (0.62 - 
1.36) 
1.54 (0.78 - 
3.05) 
None 
Hou et al., 2002 [22]   
Caucasian 
184/162  Population  0.630 (0.900)  1.27 (0.78 - 
2.05) 
0.88 (0.43 - 
1.84) 
Replication 
(random sam-
ples) 
Zhou et al., 2002 [18]  Caucasian  1092/1240  Population  0.669 (0.498)  0.98 (0.82 - 
1.17) 
1.41 (1.06 - 
1.86) 
Replication 
(random sam-
ples) 
Liang et al., 2003 [23]  Asian  1006/1020  Population  0.935 (0.294)  0.98 (0.76 - 
1.28) 
11.2 (1.45 - 
87.2) 
Replication 
(random sam-
ples) 
Misra et al., 2003 
[24] 
Caucasian  313/312  Population  0.636 (0.384)  0.76 (0.53 - 
1.07) 
0.94 (0.56 - 
1.59) 
Replication 
(random sam-
ples) 
Popanda et al., 2004 
[11] 
Caucasian  463/460  Hospital  0.630 (0.674)  1.14 (0.77 - 
1.68) 
1.03 (0.70 - 
1.51) 
Replication 
(random sam-
ples) 
Vogel et al., 2004 
[14] 
Caucasian  252/263  Population  0.644 (0.475)  1.27 (0.86 - 
1.89) 
1.09 (0.63 - 
1.86) 
None 
Shen et al., 2005 [25]  Asian  118/113  Population  0.938 (0.239)  0.58 (0.21 - 
1.52) 
— Replication 
(random sam-
ples) 
Zienolddiny et al., 
2006 [13] 
Caucasian  275/290  Population  0.622 (0.884)  0.85 (0.58 - 
1.25) 
1.11 (0.68 - 
1.81) 
Replication (all 
samples) 
 
Matullo et al., 2006 
[17] 
Caucasian  116/1094  Population  0.613 (0.635)  0.81 (0.52 - 
1.26) 
0.95 (0.51 - 
1.71) 
Replication 
(random sam-
ples) 
Summary†  No. of popu-
lations 
         
All 
 
11 
 
4110/5305 
 
 0.692 
(0.591 - 0.794) 
0.95 (0.84 - 
1.07) 
p‡ = 0.342 
1.14 (0.95 - 
1.37) 
p‡ = 0.317 
 
Caucasian 
 
8 
 
2791/3915 
 
  
0.645 
(0.572 - 0.719) 
1.12 (0.95 - 
1.32) 
p‡ = 0.178 
1.12 (0.95 - 
1.32) 
p‡ = 0.672 
 
Asian 2  (1)  1124/1133     
0.936 
(0.925 - 0.946) 
0.95 (0.73 - 
1.23) 
p‡ = 0.315 
—  
* P for difference of allelic frequency between cases and controls. 
** Crude odds ratio and 95% confidence interval. 
† Based on random effects model. 
‡ P for heterogeneity (Cochran Q test). 
Table 4. Genetic polymorphisms in the NER pathway and lung cancer risk: ERCC2 Lys751Gln polymorphism 
OR (95% CI)**  Author, published 
year (reference no.) 
Ethnicity No.  of 
Cases 
/Controls 
Source of 
controls 
Frequency of 
Lys allele (p*) 
Lys/Gln Gln/Gln 
Quality control 
of genotyping 
David-Beabes et al., 
2001 [25] 
Caucasian  178/453  Population  0.653 (0.044)  1.14 (0.77 - 
1.71) 
1.72 (1.00 - 
2.94) 
Replication 
(random sam-
ples) 
David-Beabes et al., 
2001 [25] 
African-American  153/234  Population  0.750 (0.390)  1.14 (0.73 - 
1.78) 
1.39 (0.54 - 
3.55) 
 
Replication 
(random sam-
ples) 
Spitz et al., 2001 [21]  Admixed popula-
tion 
341/360  Population  0.679 (0.257)  1.07 (0.78 - 
1.46) 
1.36 (0.84 - 
2.20) 
 
None 
Chen et al., 2002 [26]  Asian  109/109  Population  0.596 (0.050)  0.79 (0.17 - 
1.11) 
0.44 (0.17 - 
1.11) 
None Int. J. Med. Sci. 2007, 4 
 
71
OR (95% CI)**  Author, published 
year (reference no.) 
Ethnicity No.  of 
Cases 
/Controls 
Source of 
controls 
Frequency of 
Lys allele (p*) 
Lys/Gln Gln/Gln 
Quality control 
of genotyping 
Hou et al., 2002 [22]  Caucasian  185/162  Population  0.627 (0.568)  1.22 (0.75 - 
2.00) 
1.11 (0.58 - 
2.13) 
Replication 
(random sam-
ples) 
Zhou et al., 2002 [18]  Caucasian  1092/1240  Population  0.634 (0.313)  1.01 (0.84 - 
1.21) 
1.17 (0.90 - 
1.51) 
 
Replication 
(random sam-
ples) 
Park et al., 2002 [27]  Asian  250/163  Population  0.945 (0.687)  1.06 (0.55 - 
2.11) 
—  
None 
Liang et al., 2003 [19]  Asian  1006/1020  Population  0.913 (0.762)  0.93 (0.73 - 
1.18) 
2.36 (0.90 - 
6.17) 
Replication 
(random sam-
ples) 
Misra et al., 2003 [23]  Caucasian  310/302  Population  0.594 (0.978)  0.87 (0.60 - 
1.26) 
1.06 (0.64 - 
1.76) 
 
Replication 
(random sam-
ples) 
Popanda et al., 2004 
[11] 
Caucasian  463/459  Hospital  0.635 (0.104)  1.14 (0.86 - 
1.52) 
1.37 (0.93 - 
2.02) 
 
Replication 
(random sam-
ples) 
Harms et al., 2004 
[28] 
Caucasian  110/119  Population  0.727 (0.458)  1.34 (0.79 - 
2.49) 
1.07 (0.34 - 
3.38) 
 
Replication (all 
samples) 
Vogel et al., 2004 [14]  Caucasian  256/269  Population  0.652 (0.009)  1.57 (1.05 - 
2.34) 
1.73 (1.01 - 
2.96) 
None 
Shen et al., 2005 [24]  Asian  118/108  Population  0.889 (0.010)  0.44 (0.18 - 
1.03) 
— Replication 
(random sam-
ples) 
Zienolddiny et al., 
2006 [13] 
Caucasian  317/386  Population  0.631 (0.007)  1.20 (0.84 - 
1.73) 
1.56 (1.06 - 
2.31) 
 
Replication (all 
samples) 
Matullo et al., 2006 
[17] 
Caucasian  116/1094  Population  0.594 (0.475)  1.23 (0.78 - 
1.96) 
1.17 (0.63 - 
2.11) 
Replication 
(random sam-
ples) 
Summary†  No. of populations             
All 
 
15 (13) 
 
5004/6478 
 
 0.701 
(0.622 - 0.779) 
1.06 (0.97 - 
1.16) 
p‡ = 0.505 
1.30 (1.13 - 
1.49) 
p‡ = 0.495 
 
Caucasian 
 
9 
 
3027/4484 
 
  
0.634 
(0.614 - 0.655) 
1.11 (1.00 - 
1.24) 
p‡ = 0.587 
2.25 (0.97 - 
5.23) 
p‡ = 0.785 
 
Asian 4  (2)  1484/1400     
0.843 
(0.763 - 0.924) 
0.89 (0.72 - 
1.09) 
p‡ = 0.386 
1.02 (0.20 - 
5.27) 
p‡ = 0.014 
 
* P for difference of allelic frequency between cases and controls. 
** Crude odds ratio and 95% confidence interval. 
‡ P for heterogeneity (Cochran Q test).
 